Skip to main content
Clinical Trials/LBCTR2020043495
LBCTR2020043495
Not yet recruiting
Phase 3

An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITY

WHO0 sites1,000 target enrollmentNovember 4, 2020

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
COVID-19
Sponsor
WHO
Enrollment
1000
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 4, 2020
End Date
TBD
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
WHO

Eligibility Criteria

Inclusion Criteria

  • Eligibility: consenting adults (age \=18\) hospitalised with definite COVID\-19, not already receiving any of the study drugs, without known allergy or contra\-indications to any of them (in the view of the physician responsible for their care), and without anticipated transfer within 72 hours to a non\-study hospital. Patients invited to join the study will be those who are admitted to a collaborating hospital; no wider recruitment efforts are expected.

Exclusion Criteria

  • Exclusion from study entry: Patients will not be randomised if, in the view of the randomising doctor, ANY of the AVAILABLE study drugs are contra\-indicated (eg, because of patient characteristics, chronic liver or heart disease, or some concurrent medication).

Outcomes

Primary Outcomes

Not specified

Similar Trials